184 related articles for article (PubMed ID: 26707320)
1. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
[TBL] [Abstract][Full Text] [Related]
2. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
Front Immunol; 2021; 12():663602. PubMed ID: 34539621
[TBL] [Abstract][Full Text] [Related]
3. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
[TBL] [Abstract][Full Text] [Related]
5. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
6. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
7. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
10. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
12. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
13. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
14. Timing of mTORI usage and outcomes in kidney transplant recipients.
Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
[TBL] [Abstract][Full Text] [Related]
15. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis.
Cornu C; Dufays C; Gaillard S; Gueyffier F; Redonnet M; Sebbag L; Roussoulières A; Gleissner CA; Groetzner J; Lehmkuhl HB; Potena L; Gullestad L; Cantarovich M; Boissonnat P
Br J Clin Pharmacol; 2014 Jul; 78(1):24-32. PubMed ID: 24251918
[TBL] [Abstract][Full Text] [Related]
16. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
17. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
18. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Webster AC; Lee VW; Chapman JR; Craig JC
Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
[TBL] [Abstract][Full Text] [Related]
19. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis.
Jennings DL; Lange N; Shullo M; Latif F; Restaino S; Topkara VK; Takeda K; Takayama H; Naka Y; Farr M; Colombo P; Baker WL
Int J Cardiol; 2018 Aug; 265():71-76. PubMed ID: 29605470
[TBL] [Abstract][Full Text] [Related]
20. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
